AbbVie (ABBV) Total Liabilities (2012 - 2026)
AbbVie (ABBV) posted quarterly Total Liabilities of $136.5 billion for Q1 2026, little changed year-over-year from $136.2 billion in Q1 2025, and up 1.87% quarter-over-quarter from $134.0 billion in Q4 2025.
AbbVie (ABBV) Total Liabilities (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Total Liabilities for 15 consecutive years, with $136.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities changed 0.22% year-over-year to $136.5 billion; the TTM figure through Mar 2026 stood at $136.5 billion (changed 0.22% YoY), while the FY2025 annual figure was $134.0 billion, down 0.89% from the prior year.
- Total Liabilities advanced to $136.5 billion in Q1 2026 per ABBV's latest filing, from $134.0 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $148.9 billion in Q1 2024 and bottomed at $133.9 billion in Q3 2025.
- Historically, Total Liabilities has averaged $138.5 billion across 5 years, with a median of $136.5 billion in 2026.
- Annual changes were most pronounced in 2024 — Total Liabilities increased 10.65% — and 2025, when it retreated 8.54%.
- AbbVie's Total Liabilities stood at $138.8 billion in 2022, then slipped by 2.95% to $134.7 billion in 2023, then grew by 0.33% to $135.2 billion in 2024, then declined by 0.89% to $134.0 billion in 2025, then increased by 1.87% to $136.5 billion in 2026.
- Business Quant data shows ABBV's Total Liabilities at $136.5 billion in Q1 2026, $134.0 billion in Q4 2025, and $133.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 150.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 135.12 Bn |
| Mar 31, 2026 | 136.46 Bn |
| Dec 31, 2025 | 133.96 Bn |
| Sep 30, 2025 | 133.90 Bn |
| Jun 30, 2025 | 137.18 Bn |
| Mar 31, 2025 | 136.17 Bn |
| Dec 31, 2024 | 135.16 Bn |
| Sep 30, 2024 | 143.42 Bn |
| Jun 30, 2024 | 141.94 Bn |
| Mar 31, 2024 | 148.87 Bn |
| Dec 31, 2023 | 134.71 Bn |
| Sep 30, 2023 | 136.22 Bn |
| Jun 30, 2023 | 135.37 Bn |
| Mar 31, 2023 | 134.54 Bn |
| Dec 31, 2022 | 138.81 Bn |
| Sep 30, 2022 | 141.33 Bn |
| Jun 30, 2022 | 143.19 Bn |
| Mar 31, 2022 | 143.21 Bn |
| Dec 31, 2021 | 146.53 Bn |
| Sep 30, 2021 | 148.86 Bn |